logo

Astellas Pharma Inc. (ALPMY)



Trade ALPMY now with
  Date
  Headline
9/12/2022 9:02:23 AM Astellas Reports Results Of Trial Of PADCEV -KEYTRUDA &PADCEV As Monotherapy In First-Line Advanced Urothelial Cancer
8/18/2022 2:34:47 AM FDA Accepts Astellas' NDA For Fezolinetant For Treatment Of Vasomotor Symptoms Associated With Menopause
7/26/2022 4:22:18 AM Astellas, Seagen Announce Positive Topline Results For PADCEV With KEYTRUDA For Advanced Urothelial Cancer
7/5/2022 3:02:32 AM Mogrify , Astellas To Conduct Research On In Vivo Regenerative Medicine Approaches To Address Sensorineural Hearing Loss
6/26/2022 8:39:31 PM Astellas Pharma : FDA Places Clinical Hold On FORTIS Phase 1/2 Trial Of AT845 In Adults With Late-Onset Pompe Disease
6/1/2022 12:06:36 AM Astellas, GO Therapeutics Enter Strategic Research And License Deal To Develop Novel Antibodies For Immuno-Oncology
4/27/2022 2:53:51 AM Astellas Pharma FY EPS 103.03 Yen Vs 113.03 Yen Last Year
4/25/2022 2:03:03 AM University Of Tokyo, Astellas Enter Into Partnership For Co-creation Of New Medicines And Medical Solutions